Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole Effect on Mifepristone Pharmacokinetics
NCT03259542Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Aug 2017
- Primary completion
- Dec 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mifepristone in Cushing's syndrome, sponsored by Corcept Therapeutics. Primary endpoints: Maximum Plasma Concentration of mifepristone at Day 42 and Area Under the Plasma Concentration-Time Curve from 0 to 24 hours of mifepristone. Started Aug 2017; status: completed.
02
Drugs
mifepristone
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT03259542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259542.